Patient Safety Movement Foundation Honors Ruth Ann Dorrill, Kimberly Cripe, Dr. Peter Lachman with Humanitarian Awards and Dr. Mike Durkin with Lifetime Achievement Award
10.9.2024 06:40:00 CEST | Business Wire | Press release
Capping an eventful two days at the 11th Annual World Patient Safety, Science & Technology Summit, the Patient Safety Movement Foundation (PSMF) presented its prestigious Humanitarian Awards to visionaries and change agents in patient safety. The honorees were Ruth Ann Dorrill, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General; Kimberly Chavalas Cripe, the President and Chief Executive Officer at Children’s Hospital of Orange County; and Dr. Peter Lachman, Lead, Faculty Quality Improvement, Royal College of Physicians of Ireland. A special Lifetime Achievement Award was given to Dr. Mike Durkin, Chair of the PSMF’s Governance Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909880433/en/
2024 Humanitarian Award recipients (left column, from top to bottom): Ruth Ann Dorrill, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General, with Joe Kiani and Dr. Mike Durkin; Kimberly Chavalas Cripe, the President and Chief Executive Officer at Children’s Hospital of Orange County, with Joe Kiani; Dr. Peter Lachman, Lead, Faculty Quality Improvement, Royal College of Physicians of Ireland, with Joe Kiani and Dr. Mike Durkin. Main image (right): Joe Kiani presents Dr. Mike Durkin with Lifetime Achievement Award. (Photo: Business Wire)
Each year since 2013, the PSMF’s Humanitarian Award is presented to a select group of distinguished individuals who have left an indelible mark on healthcare and helped shape the future of patient safety. As visionary leaders in their respective fields, they have implemented innovative, evidence-based, and sustainable solutions that transform the landscape of healthcare safety. This award honors their outstanding achievements so that they may serve as beacons of hope and sources of inspiration in the pursuit of zero harm and creating a safer, more just healthcare system for all.
The PSMF Lifetime Achievement Award is the highest award the PSMF can bestow. This individual will have made significant contributions in the area of patient safety throughout their career, and their achievements will have helped propel the medical community toward zero preventable patient and healthcare worker harm.
“It’s an honor to work with such a dedicated group of individuals whose contributions toward advancing patient safety are saving lives,” said PSMF Founder Joe Kiani. “As everyone in this field knows, we can’t do it alone, and these individuals represent the mentors we need to eliminate preventable patient harm in our hospitals and create a safer healthcare system for all.”
Ruth Ann Dorrill works for the U.S. Department of Health and Human Services as the Assistant Inspector General in the Office of Evaluation and Inspections, Office of Inspector General (OIG). Dorrill has been with the OIG for 28 years, leading the OIG’s work in patient harm for 15 years. She has led national studies in evaluating hospital and nursing quality, safety, and emergency preparedness, and has directed management reviews of HHS programs, including the Centers for Medicare & Medicaid Services implementation of HealthCare.gov and management of the Indian Health Service. She has testified before the U.S. House of Representatives Energy and Commerce Committee regarding nursing home quality and in 2021 received the Council of the Inspectors General on Integrity and Efficiency Lifetime Achievement Award.
As the President and Chief Executive Officer of Children’s Hospital of Orange County (CHOC) since 1997, Kimberly Chavalas Cripe has made significant advances in improving patient care, outcomes, and experience, while cultivating a growing healthcare community rooted in a culture of safety, excellence, innovation, and collaboration. Under Cripe’s leadership, CHOC has become a forerunner of population health management with the singular goal of fulfilling CHOC’s mission to advance and protect the health and well-being of children. Among many other initiatives, Cripe spearheaded efforts at CHOC to establish a robust pediatric system of mental healthcare designed to be scalable and replicable by other health systems. Cripe also serves as president of the CHOC Foundation, which raises funds to support pediatric healthcare.
Dr. Peter Lachman serves as Lead, Faculty Quality Improvement, at the Royal College of Physicians of Ireland (RCPI) in Dublin, where he directs the Leadership and Quality program to develop clinical leaders in quality improvement. He was Chief Executive Officer of the International Society for Quality in Healthcare (ISQua) from 2016 to 2021 and was a Health Foundation Quality Improvement Fellow at the Institute for Healthcare Improvement in 2005–2006. Dr. Lachman was also the National Clinical Lead for SAFE, a Royal College of Paediatrics and Child Health program that aims to improve situation awareness in clinical teams across England and Ireland. In addition, his work for PSMF includes editing Handbook publications on patient safety, medical management, and quality improvement, and leading the Global Interprofessional Patient Safety Fellowship program.
Dr. Mike Durkin, who is the current Chair of the Patient Safety Movement Foundation’s Governance Board, was honored with a special Lifetime Achievement Award by PSMF Founder Joe Kiani. In addition to his work for PSMF, Dr. Durkin is the Senior Advisor on Patient Safety Policy and Leadership, Institute of Global Health Innovation, Imperial College London. He is recognized as one of the world’s foremost authorities on patient safety and holds numerous advisory positions, serving as Senior Advisor on Patient Safety Policy and Leadership for the NIHR Imperial College Patient Safety Translational Research Centre in the U.K., and Academic Director of the Global Patient Safety Collaborative, a partnership between the World Health Organization (WHO) and the U.K. government. Dr. Durkin previously held clinical, research, and teaching positions in cardiovascular anesthesia and critical care in the U.K. and the U.S. before embarking on a 25-year career in medical management and leadership, culminating in an appointment as National Health Service (NHS) Medical Director across the South of England. Durkin subsequently served as the NHS National Director of Patient Safety.
PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909880433/en/
Contacts
Patient Safety Movement Foundation
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom